Our researchers have comprehensive experience with all major imaging modalities and applications in multiple therapeutic areas. See below for a list of recently published abstracts and manuscripts that we have co-authored or supported/acknowledged. For information about where our scientists are presenting and speaking about our work, please visit our Events page.  Please find here a small selection of recent publications:

  • The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva is Activin A-Dependent†

  • Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans.

  • Three-Dimensional Dosimetry for Radiation Safety Estimates from Intrathecal Administration

  • High-throughput high-volume nuclear imaging for preclinical in vivo compound screening

  • The phosphodiesterase 10 positron emission tomography tracer, 18FMNI-659, as a novel biomarker for early Huntington disease

  • Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET)

  • In vivo evaluation of 18F-MNI698: an 18F-labeled radiotracer for imaging of serotonin 4 receptors in brain

  • Automated segmentation of MR imaging to determine normative central nervous system cerebrospinal fluid volumes in healthy volunteers

  • Whole-body biodistribution and dosimetry estimates of a novel radiotracer for imaging of serotonin 4 receptors in brain: 18FMNI-698

  • 14C-2-deoxyglucose autoradiography screen for mouse brain activity: relating known therapeutics and novel compounds for schizophrenia, depression, and bipolar disorder to brain circuitry

    A. GIOVANNI, S. ENGEL, C. BOWEN, R. TERRY-LORENZO, P. G. JONES, L. HARDY, T. LARGE, T. HANANIA, E. V. SABATH, V. ALEXANDROV, M. QUTAISH, M. SEAMAN, P. CZARNECKI, M. SILVA, J. SULLIVAN…
  • Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β

  • The Effect of Bolus Volume and Mechanical Forces on the Biodistribution of ASOs Following Lumbar Intrathecal Administration in Cynomolgus Monkeys (S38.007)

  • Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer’s Disease Subjects

  • Synthesis and in vivo Evaluation of Fluorine-18 and Iodine-123 Pyrazolo 4,3-e -1,2,4-triazolo 1,5-c pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A2A Receptors

  • Cerebellar Amyloid-b Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?

  • Comparison of 11CTZ1964B and 18FMNI659 for PET imaging brain PDE10A in nonhuman primates

  • Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer’s Disease Subjects

  • Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging

  • A dual-isotope 3D Cryo-Imaging Quantitative Autoradiography (CIQA) Method for Simultaneous and Quantitative Assessment of both Antibody and Drug Conjugate Tumor Distribution and Kinetics

  • 3D Cryo-Imaging and Quantitative Autoradiography (CIQA) for the Evaluation of Radiolabeled Drugs Targeting to Tumor Cells

  • The Use of PET/CT and Autoradiography to Assess the Distribution of a 124-I Labeled Exogenous Protein Following Intranasal Delivery in Cynomolgus Macaques

  • The Use of Power Analysis in Small Sample Pre-clinical Imaging Studies

  • Development and Optimization of Standalone Multi-Wavelength Fluorescence Add-on for a Cryoslicer

  • Development of enzyme mediated imaging and therapy (EMIT) as a novel theragnostic agent for metastatic prostate cancer

  • A Gradient-Loadable (64)Cu-chelator for Quantifying Tumor Deposition Kinetics of Nanoliposomal Therapeutics by PET

    Nanomedicine. 2015 Jan;11(1):155-65. doi: 10.1016/j.nano.2014.08.011. Epub 2014 Sep 6. SEE MORE…
  • Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling

    PLoS One. 2014 May 8;9(5):e97084. doi: 10.1371/journal.pone.0097084. eCollection 2014. SEE MORE…

  • Optimizing Central Nervous System Drug Development Using Molecular Imaging

    Clin Pharmacol Ther. 2015 Jul;98(1):47-60. doi: 10.1002/cpt.132. Epub 2015 May 19. SEE MORE…

  • CIQuanT – Bridging the Gap between In Vivo and Ex Vivo Imaging by using Quantitative Whole Body Autoradiography (QWBA), 3D Cryo-Imaging (3DC) Techniques, and PET/CT

    2015 International Symposium on Biomedical Imaging; Session: Imaging Applications in the Biopharmaceutical Industry. SEE MORE…

  • Multivariate Study Using Short- and Long-lived Radioisotopes, In Vivo PET/CT and Planar Scintigraphy, and Ex Vivo Autoradiography to Assess Biodistribution and Pharmacokinetics of Bone-Targeting Test Material in a Canine Model

  • PET/CT clinical protocol design for the novel, first in class 68Ga labeled guanylyl cyclase C targeted peptide MLN6907

    AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. SEE MORE…

  • Receptor occupancy and tumor penetration by antibodies, peptides, and antibody fragments: Molecular simulation of imaging assessment

    AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. SEE MORE…

  • Using radionuclear imaging and mechanistic modeling to assess the therapeutic potential of antibody-drug conjugates (ADCs)

    AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. SEE MORE…

  • In vitro and in vivo investigation of the novel, first-in class, Guanylyl Cyclase C (GCC) targeted 68Ga labeled heat stable peptide MLN6907 for tumor imaging

    AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA.  SEE MORE…

  • First-in class in vivo imaging of guanylyl cyclase c (GCC) in subcutaneous xenografts

    AACR/SNMMI State-of-the-Art Molecular Imaging in Cancer Biology and Therapy: Abstracts. SEE MORE…

  • FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes

    Published: April 23, 2015 DOI: 10.1371/journal.pone.0124930c.  SEE MORE…

  • Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates

    EJNMMI Research 2015, 5:24  SEE MORE…

  • Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer

    J Biol Chem. 2015 Mar 20; 290(12): 7345–7359. SEE MORE…

  • Cryoflourescence Tomography (CFT) is an Ex Vivo Tool to Study Anatomy, Physiology, and Drug or Tracer Distribution in Brain and Other Organs

    Ex vivo imaging methodologies such as immunohistochemistry, fluorescence imaging, and autoradiography have been used to study anatomy, physiology and drug or tracer distribution in either whole bodies or excised organs.  These methodologies can follow and accompany in vivo imaging studies or serve as stand-alone studies themselves.  Because ex vivo processing is relatively expensive and time consuming, often sections and/or images are taken at large intervals (0.1-1 mm) throughout the entire specimen.  Information is lost in these gaps where sections are not collected or imaged.  Further, if a three dimensional model of the specimen is required, interpolation of largely spaced sections is required and the model may suffer.  We sought to address some of these potential drawbacks by capturing high resolution white light and multispectral (700 and 800 nm) fluorescence images off the block after every pass of the micro or macrotome blade using an intraoperative fluorescence imaging system (Curadel, LLC, Worcester, MA), thus vastly improving the amount of information captured throughout the specimen and decreasing total acquisition time.  We have termed the process of fluorescent and high resolution white light data collection and subsequent co-registration and/or three-dimensional reconstruction, cryofluorescence tomography or CFT. Using our CFT methodology, organs or small animal whole bodies are sectioned at 25 microns and all images are captured and acquired in less than 2 hours, improving some shortcomings of various ex vivo techniques, while enabling the creation of high resolution 3D models.

    Marc Seaman, Robert Holt, Paige Czarnecki, Jacob Hesterman, Shailendra Patel, Jack Hoppin, John Frangioni, Ajay Verma

    Please contact us at info@invicro.com for access to this poster.

  • Pharmacokinetic and Pharmacodynamic Imaging of Intrathecally Administered Antisense Oligonucleotides

    Antisense oligonucleotides (ASOs) are promising drugs for treating CNS disorders due to their specific targeting and extended pharmacological effect. The development of therapeutics for CNS disorders has been impeded by the inability of most drug molecules to cross the blood brain barrier (BBB) and engage their targets. The intrathecal (IT) dosing route offers a solution for bypassing the BBB and delivering drugs directly to the CNS. However, determining the pharmacokinetics (PK) and pharmacodynamics (PD) presents unique challenges imposed by anatomical and functional properties of the IT space and reliance upon ex vivo histological molecular techniques. We developed an imaging approach using radio and fluorophore-labeled ASOs tracking PK and also employed neuroreceptor targeting ASOs to enable tracking of PD using receptor-targeting radiotracers. Two ASOs were evaluated in this study, one that targets the GABRA1 gene and is expected to reduce GABA A receptor alpha1 activity, the other targeting the MALAT1 housekeeping gene as a control treatment.

    Ken Zasadny, Jenna M. Sullivan, Daniel A. Wolf, Curt Mazur, Berit Powers, Jacob Hesterman, Marc Seaman, Robert W. Holt, Mohammed Qutaish, Ildiko Polyak, Richard Coelho, Vijay Gottumukkala, Carolynn M. Gaut, Jack Hoppin, Eric E. Swayze, Ajay Verma

    Please contact us at info@invicro.com for access to this poster.

  • SPECT Imaging in a Mouse Model of Muscular Dystrophy: MDX mice have a higher uptake of 99mTc-MDP in muscle than healthy age-matched controls

    99mTc-MDP is an in vivo bone imaging agent that has been shown to highlight the inflammatory process and bone and muscle calcification in a wide range of osseous and non-osseous disorders. Histological studies of muscle from C57BL/10ScSn-Dmdmdx (MDX) mice have found degenerative lesions with calcification. The objective of this study was to image calcified lesions with 99mTc-MDP in a mouse model of muscular dystrophy. Subjects included male MDX mice (n=5) and controls (n=5). Mice were administered 99mTc-MDP intravenously (~700 µCi/animal) while awake and were allowed to be freely moving after tracer . Mice were anesthetized with isoflurane just prior to imaging and for the duration of each scan and were imaged on the nanoSPECT/CT (Mediso, Budapest, Hungary).  A 1x20min static whole-body SPECT scan was acquired followed by CT at 2 hours after tracer injection. Mice were imaged at 6, 15, and 19 weeks of age. After the final in vivo imaging timepoint, animals were euthanized, perfused and imaged post-life at ~3 hours post injection. Following post-life imaging, the diaphragm was resected from each animal, fixed in a formalin gel, and imaged ex vivo with SPECT/CT. Regions of interest were defined for the scapular muscles, heart, kidneys, quadriceps, skeleton, and diaphragm. Concentration (in SUV) of 99mTc-MDP in these regions was compared between groups at different time points.  At all imaging timepoints, 99mTc-MDP concentrations in the heart, left and right quadriceps were significantly (p<0.05) higher in MDX mice than controls. 99mTc-MDP concentrations in the left and right scapular muscles were also higher in MDX mice than control but only significantly higher in the right scapular at 6 weeks and left and right scapular at 15 weeks.  Post-life imaging was consistent with in vivo imaging at the week 16 timepoint. In ex vivo diaphragm imaging, 99mTc-MDP signal was noticeably higher in the diaphragms from MDX mice. The MDX mouse model of Duchenne Muscular Dystrophy shows greater uptake of 99mTc-MDP in muscle, particularly the quadriceps and diaphragm, as compared with controls. This agrees with histological reports of muscle calcification in MDX mice, and suggests that 99mTc-MDP could be a useful imaging assay in Muscular Dystrophy.

    Carolynn M. Gaut, Jenna M, Sullivan, Whitney Woodson, Andrew W. Novicki, Edward J. Soares, Andy Sweet, Molly J Leen, Mark Lane, Dustin Kentala, Jacob Hesterman, Jack Hoppin, Ajay Verma

    Please contact us at info@invicro.com for access to this poster.